Skip to main content
Rahnab Pharmed Investment Holding
FA / EN
Rahnab Pharmed Investment Holding
  • 01 Home
  • 02 About Us
  • 03 Strategic Capabilities
  • 04 Subsidiaries
    Nozhin Zist Pharmed Tamin Plasma Nozhin Baya Zist Pharmed Padra Serum Alborz Persis Gene Par KarayaKhteh Tejhiz Azma Nivad Pharmed Salamat
  • 05 News & Events
  • 06 Contact Us

Holding Headquarters

Tehran, Km 15 Tehran-Karaj Highway, National Institute of Genetic Engineering and Biotechnology (NIGEB), 3rd Floor, Suite 302

Direct Contact Information

02144787260 info@rahnab.com
© 2026 RAHNAB PHARMED HOLDING
  1. Home
  2. /
  3. Category: <span>Advanced Tech & Therapeutics</span>

Category: Advanced Tech & Therapeutics

Sep 18, 2024

KarayaKhteh Achieves Success in Phase I Clinical Trial of CAR-T Cell Immunotherapy

Official entry into the elite club of advanced cancer cellular therapy manufacturers in West Asia.

View Full Details
Aug 1, 2024

Persis Gene Accelerator Commences New Cohort of Biopharma Acceleration Teams

Entry of six elite health biotechnology startups into formulation R&D and holding venture financing.

View Full Details
Rahnab Pharmed

Architect of Iran's modern biotechnology value chain. Specialized investment in sovereign healthcare infrastructure and national pharmaceutical self-sufficiency.

info@rahnab.com 02144787260

Quick Links

  • About Holding
  • Strategic Capabilities
  • Subsidiaries
  • National Impact
  • News & Milestones

Subsidiaries

  • Nozhin Zist Pharmed ↗
  • Tamin Plasma Nozhin ↗
  • Baya Zist Pharmed ↗
  • Padra Serum Alborz ↗
  • Persis Gene Par ↗
  • KarayaKhteh Tejhiz Azma ↗
  • Nivad Pharmed Salamat ↗

Holding Headquarters

Tehran, Km 15 Tehran-Karaj Highway, National Institute of Genetic Engineering and Biotechnology (NIGEB), 3rd Floor, Suite 302

© 2026 All rights reserved for Rahnab Pharmed Investment Holding.

Designed & Developed by HashtBehesht

PORTAL PARTNERSHIP

Send Message & Partnership Inquiry

Please fill out the form below; our corporate representatives will contact you shortly.